Amneal Pharmaceuticals, Inc. AMRX Legal contingency and settlement
Legal contingency and settlement at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s legal contingency and settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s legal contingency and settlement?
- Amneal Pharmaceuticals, Inc. (AMRX) reported legal contingency and settlement of -$694K in Q1 2026.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s legal contingency and settlement?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s legal contingency and settlement has grown at a -64.7% compound annual growth rate (CAGR), from -$25M to $390K.
- What does legal contingency and settlement mean?
- This metric reflects the financial impact of legal settlements, judgments, or contingency resolutions arising from litigation involving the company's business operations. It captures both the costs of settling disputes and any gains recognized from favorable legal outcomes. Tracking this metric is essential for evaluating the company's exposure to legal liabilities and the potential volatility these non-recurring events introduce to operating performance.